Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026)
Contineum Therapeutics' (CTNM) quarterly Income from Continuing Operations came in at 38445000.0 in Q1 2026, down 76.6% year-on-year from 164268429.83 in Q1 2025, and down 60.09% quarter-over-quarter from 24015000.0 in Q4 2025.
Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 38445000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 76.6% year-over-year to 38445000.0 in Q1 2026; TTM through Mar 2026 was 117965000.0, a 112.13% decrease from a year earlier, with the FY2025 full-year figure at 115830000.0, down 174.1% from the prior year.
- Income from Continuing Operations fell to 38445000.0 in Q1 2026 per CTNM's latest filing, from 24015000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 41571000.0 in Q2 2023 and bottomed at 38445000.0 in Q1 2026.
- The 4-year median for Income from Continuing Operations is 10267000.0 (2024), against an average of 12219230.77.
- Across the five-year window, Income from Continuing Operations sank 63.77% in 2024 and sank 237.7% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 7335000.0 in 2023, then plunged by 98.57% to 14565000.0 in 2024, then sank by 64.88% to 24015000.0 in 2025, then slumped by 60.09% to 38445000.0 in 2026.
- Per Business Quant, the three latest CTNM Income from Continuing Operations figures stand at 38445000.0 (Q1 2026), 24015000.0 (Q4 2025), and 34672000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Contineum Therapeutics | 536.56 Mn | 536.56 Mn | - | -38.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.45 Mn |
| Dec 31, 2025 | -24.02 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Mar 31, 2025 | -21.77 Mn |
| Dec 31, 2024 | -14.57 Mn |
| Sep 30, 2024 | -10.27 Mn |
| Jun 30, 2024 | -9.01 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Dec 31, 2023 | -7.34 Mn |
| Sep 30, 2023 | -6.27 Mn |
| Jun 30, 2023 | 41.57 Mn |
| Mar 31, 2023 | -4.82 Mn |